• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Relay Therapeutics Inc. (Amendment)

    2/14/24 4:20:24 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RLAY alert in real time by email
    SC 13G/A 1 d10823826_13g-a.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Relay Therapeutics, Inc.
    (Name of Issuer)

     

     

    Common Stock, par value $0.001 per share
    (Title of Class of Securities)

     

     

    75943R102
    (CUSIP Number)

     

     

    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [_] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    __________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    CUSIP No 75943R102    

     

    1. NAME OF REPORTING PERSONS  
         
      Casdin Capital, LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      7,387,943  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      7,387,943  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      7,387,943  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
             [_]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.99%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IA

     

     

     

     

    CUSIP No 75943R102    

     

         
    1. NAME OF REPORTING PERSONS  
         
      Casdin Partners Master Fund, L.P.  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Cayman Islands  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      6,439,369  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      6,439,369  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      6,439,369  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.22%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    PN

     

     

     

     

     

     

     

    CUSIP No 75943R102    

     

    1. NAME OF REPORTING PERSONS  
         
      Casdin Partners GP, LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      6,969,369  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      6,969,369  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      6,969,369  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
             [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.65%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

     

     

     

    CUSIP No 75943R102    

     

    1. NAME OF REPORTING PERSONS  
         
      Eli Casdin  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States of America  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      7,387,943  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      7,387,943  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      7,387,943  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
             [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.99%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN, HC

     

     

     

     

    CUSIP No 75943R102    

     

    Item 1. (a). Name of Issuer:  
           
        Relay Therapeutics, Inc.  

     

      (b). Address of Issuer's Principal Executive Offices:  
           
       

    399 Binney Street, 2nd Floor

    Cambridge, Massachusetts 02139

     

     

    Item 2. (a). Name of Person Filing:  
           
       

    Casdin Capital, LLC

    Casdin Partners Master Fund, L.P.

    Casdin Partners GP, LLC

    Eli Casdin

     

     

      (b). Address of Principal Business Office, or if None, Residence:  
           
       

    Casdin Capital, LLC

    1350 Avenue of the Americas, Suite 2600

    New York, New York 10019

     

    Casdin Partners Master Fund, L.P.

    1350 Avenue of the Americas, Suite 2600

    New York, New York 10019

     

    Casdin Partners GP, LLC

    1350 Avenue of the Americas, Suite 2600

    New York, New York 10019

     

    Eli Casdin

    1350 Avenue of the Americas, Suite 2600

    New York, New York 10019

     

     

      (c). Citizenship:  
           
       

    Casdin Capital, LLC - Delaware

    Casdin Partners Master Fund, L.P. - Cayman Islands

    Casdin Partners GP, LLC - Delaware

    Eli Casdin– United States of America

     

     

      (d). Title of Class of Securities:  
           
        Common Stock, par value $0.001 per share  

     

      (e). CUSIP Number:  
           
        75943R102  

     

     

     

    Item 3. If This Statement is filed pursuant to ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a

     

      (a) [_] Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).
           
      (b) [_] Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
           
      (c) [_] Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
           
      (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) [_] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
      (f) [_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
      (g) [_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
           
      (i) [_] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j)   [_] Group, in accordance with s.240.13d-1(b)(1)(ii)(J).

     

    Item 4. Ownership.

     

      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)   Amount beneficially owned:
         
       

    7,387,943 shares deemed beneficially owned by Casdin Capital, LLC

    6,439,369 shares deemed beneficially owned by Casdin Partners Master Fund, L.P.

    6,969,369 shares deemed beneficially owned by Casdin Partners GP, LLC

    7,387,943 shares deemed beneficially owned by Eli Casdin

     

      (b)   Percent of class:
         
       

    5.99% deemed beneficially owned by Casdin Capital, LLC

    5.22% deemed beneficially owned by Casdin Partners Master Fund, L.P.

    5.65% deemed beneficially owned by Casdin Partners GP, LLC

    5.99% deemed beneficially owned by Eli Casdin

     

      (c)   Number of shares as to which Casdin Capital, LLC has:

     

      (i) Sole power to vote or to direct the vote 0 ,
           
      (ii) Shared power to vote or to direct the vote 7,387,943 ,
           
      (iii) Sole power to dispose or to direct the disposition of 0 ,
           
      (iv) Shared power to dispose or to direct the disposition of 7,387,943 .

     

     

     

     

      Number of shares as to which Casdin Partners Master Fund, L.P. has:

     

      (i) Sole power to vote or to direct the vote 0 ,
           
      (ii) Shared power to vote or to direct the vote 6,439,369 ,
           
      (iii) Sole power to dispose or to direct the disposition of 0 ,
           
      (iv) Shared power to dispose or to direct the disposition of 6,439,369 .

     

     

      Number of shares as to which Casdin Partners GP, LLC has:

     

      (i) Sole power to vote or to direct the vote 0 ,
           
      (ii) Shared power to vote or to direct the vote 6,969,369 ,
           
      (iii) Sole power to dispose or to direct the disposition of 0 ,
           
      (iv) Shared power to dispose or to direct the disposition of 6,969,369 .

     

      Number of shares as to which Eli Casdin has:

     

      (i) Sole power to vote or to direct the vote 0 ,
           
      (ii) Shared power to vote or to direct the vote 7,387,943 ,
           
      (iii) Sole power to dispose or to direct the disposition of 0 ,
           
      (iv) Shared power to dispose or to direct the disposition of 7,387,943 .

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

     

         
     

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

     

     

    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

     

      N/A
       

     

     

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

     

    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

     

      N/A
       

     

    Item 8. Identification and Classification of Members of the Group.

     

     

    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.

     

      N/A
       

     

    Item 9. Notice of Dissolution of Group.

     

     

    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

     

      N/A
       

     

    Item 10. Certification.

     

      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

        February 14, 2024  
        (Date)  

     

     

    Casdin Capital, LLC*

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)

     

     

    Casdin Partners Master Fund, L.P.*

    By: Casdin Partners GP, LLC, its general partner

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)

     

     

    Casdin Partners GP, LLC*

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)
       
       
      /s/ Eli Casdin*
      Eli Casdin

     

     

     

    * The Reporting Persons disclaim beneficial ownership in the Shares reported herein except to the extent of their pecuniary interest therein.

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     

    Exhibit A

    AGREEMENT

    The undersigned agree that this Schedule 13G amendment dated February 14, 2024 relating to the Common Stock, par value $0.001 per share of Relay Therapeutics, Inc., shall be filed on behalf of the undersigned. 

     

    Casdin Capital, LLC

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)

     

     

    Casdin Partners Master Fund, L.P.

    By: Casdin Partners GP, LLC, its general partner

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)

     

     

    Casdin Partners GP, LLC

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)
       
       
      /s/ Eli Casdin
      Eli Casdin

     

     

     

     

     

     

     

     

    Get the next $RLAY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RLAY

    DatePrice TargetRatingAnalyst
    1/26/2026$14.00Perform → Outperform
    Oppenheimer
    12/12/2025$13.00Equal Weight → Overweight
    Wells Fargo
    9/4/2025$15.00Buy
    Guggenheim
    4/17/2025$4.00Equal Weight
    Wells Fargo
    9/10/2024$20.00Buy
    Goldman
    9/10/2024Outperform → Perform
    Oppenheimer
    9/10/2024$10.60 → $16.00Hold → Buy
    Jefferies
    5/10/2024$15.00Equal Weight → Overweight
    Barclays
    More analyst ratings

    $RLAY
    SEC Filings

    View All

    SEC Form 8-K filed by Relay Therapeutics Inc.

    8-K - Relay Therapeutics, Inc. (0001812364) (Filer)

    5/21/26 5:07:30 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B5 filed by Relay Therapeutics Inc.

    424B5 - Relay Therapeutics, Inc. (0001812364) (Filer)

    5/21/26 4:12:37 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B5 filed by Relay Therapeutics Inc.

    424B5 - Relay Therapeutics, Inc. (0001812364) (Filer)

    5/19/26 5:15:57 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RLAY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June

    CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in June: 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 12:45 p.m. ETGoldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 8:40 a.m. ET The fireside chats will be webcast live and may be accessed through Relay Therapeutics' website under Events in the News & Events section through the following link: https://

    5/27/26 4:05:00 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Relay Therapeutics Announces Pricing of Public Offering of Common Stock

    CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, announced today the pricing of an underwritten public offering of 22,916,667 shares of its common stock at a public offering price of $12.00 per share. Relay Therapeutics also granted the underwriters a 30-day option to purchase up to an additional 3,437,500 shares of its common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $275 milli

    5/20/26 8:21:22 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Relay Therapeutics Announces Proposed Public Offering of Common Stock

    CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, announced today that it has commenced an underwritten public offering of $175 million of shares of its common stock. Relay Therapeutics also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the shares in the proposed offering are to be sold by Relay Therapeutics. Jefferies, TD Cowen, Goldman Sachs & Co. LLC and Guggenhei

    5/19/26 4:03:00 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RLAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Relay Therapeutics upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Relay Therapeutics from Perform to Outperform and set a new price target of $14.00

    1/26/26 8:32:07 AM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Relay Therapeutics upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Relay Therapeutics from Equal Weight to Overweight and set a new price target of $13.00

    12/12/25 8:37:26 AM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim resumed coverage on Relay Therapeutics with a new price target

    Guggenheim resumed coverage of Relay Therapeutics with a rating of Buy and set a new price target of $15.00

    9/4/25 9:07:32 AM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RLAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Catinazzo Thomas sold $227,841 worth of shares (17,717 units at $12.86) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 195,178 units (SEC Form 4)

    4 - Relay Therapeutics, Inc. (0001812364) (Issuer)

    5/14/26 6:44:36 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Catinazzo Thomas sold $14,376 worth of shares (972 units at $14.79), decreasing direct ownership by 0.45% to 212,895 units (SEC Form 4) to satisfy tax liability

    4 - Relay Therapeutics, Inc. (0001812364) (Issuer)

    4/30/26 4:22:54 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Rahmer Peter sold $11,137 worth of shares (753 units at $14.79), decreasing direct ownership by 0.27% to 275,857 units (SEC Form 4) (tax withholding)

    4 - Relay Therapeutics, Inc. (0001812364) (Issuer)

    4/30/26 4:22:24 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RLAY
    Leadership Updates

    Live Leadership Updates

    View All

    Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

    CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company's Board of Directors, effective June 9, 2025. "It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-stage oncology to offer guidance as we prepare to initiate our Phase 3 ReDiscover-2 trial in breast cancer soon," said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics.

    6/11/25 4:05:00 PM ET
    $BCAX
    $RLAY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Section 32 Raises $740 Million Venture Fund

    SAN DIEGO, Nov. 4, 2021 /PRNewswire/ -- Section 32 announced today the closing of its fourth fund, raising approximately $740 million from returning and new investors. Investors in Fund 4 include leading philanthropic and non-profit organizations, educational endowments and foundations, and leaders from the technology and healthcare sectors. Section 32 Fund 4 will support companies across all stages that are pioneering innovations at the forefront of technology and healthcare. With the closing of its oversubscribed Fund 4 and to support its continued growth, Section 32 also announced the appointment of Nina Labatt to the role of Chief Operating Officer and Chief Financial Officer.

    11/4/21 8:14:00 AM ET
    $COIN
    $CRWD
    $EXAS
    Finance: Consumer Services
    Finance
    Computer Software: Prepackaged Software
    Technology

    Octant Bio Appoints Industry Veteran Mark Murcko as Strategic Advisor and Board Member

    Murcko brings over 30 years of chemistry development in biotech experience to the synthetic biology startup Today, Octant, a therapeutics company integrating novel high-throughput experimental technologies with computation to solve complex challenges in drug discovery, announced the appointment of Mark Murcko as Strategic Advisor and Board Member. Murcko brings over three decades of industry experience, having been at the center of many transformational biotech efforts, most recently as founding CSO and Board Member of Dewpoint Therapeutics. Murcko is working closely with the company to scale Octant to its next phase of growth and further develop its chemistry platform. This press release

    10/14/21 8:00:00 AM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RLAY
    Financials

    Live finance-specific insights

    View All

    Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies

    Promising initial efficacy data with 60% volumetric response rate across doses and 29%* at the lowest tested dose of 100mg twice daily (BID) with all patients ongoing Interim investigator- and patient-reported outcomes show 89% and 79% of patients achieved clinical improvement at week 12, respectively, and support the potential of zovegalisib to drive clinically meaningful benefit for patients Evaluation across a wide dose range confirms potential therapeutic window, with interim safety profile supportive of chronic dosing and no patients discontinuing treatment due to adverse events Expansion cohorts for adults and adolescents opened at 400mg once daily (QD) and 300mg BID;pediatric

    5/19/26 6:00:00 AM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates

    FDA Breakthrough Therapy designation granted to zovegalisib for PIK3CA-mutant, HR+/HER2- advanced breast cancer, the Phase 3 ReDiscover-2 trial population in 2L breast cancer Presented zovegalisib doublet data at Phase 3 dose in CDK4/6-experienced patients at ESMO TAT, demonstrating 11.1-month median PFS with similar efficacy in kinase and non-kinase mutations Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine-sensitive patients expected to initiate in early 2027 Initiated Phase 1/2 trial of RLY-8161, a NRAS-selective molecule, in patients with NRAS-mutant solid tumors Initial vascular anomalies clinical data conferenc

    5/5/26 4:05:00 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer

    Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline development Compelling efficacy and tolerability data for zovegalisib triplet in median 3L patients 44% ORR in heavily pre-treated, CDK4/6-experienced patients (median third-line); ORR is similar across kinase and non-kinase PIK3CA mutations Phase 3 frontline trial in endocrine sensitive patients expected to initiate in early 2027, subject to regulatory feedback Supply agreement in place with Pfizer to supply atirmociclib for the Phase 3 frontline trial Relay Therapeutics to host a conference call today, April 27, at 8:30am ET CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ

    4/27/26 6:00:00 AM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RLAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Relay Therapeutics Inc.

    SC 13G/A - Relay Therapeutics, Inc. (0001812364) (Subject)

    11/14/24 1:22:38 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Relay Therapeutics Inc. (Amendment)

    SC 13G/A - Relay Therapeutics, Inc. (0001812364) (Subject)

    2/14/24 4:20:24 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Relay Therapeutics Inc.

    SC 13G - Relay Therapeutics, Inc. (0001812364) (Subject)

    2/14/24 10:03:03 AM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care